{"disease":{"id":"cd19-negative-b-cell-malignancies","name":"cd19 negative b cell malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04430530","title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}